Upper Versus Middle‐Neck Involvement in TNM ‐9 Stage IB Nasopharyngeal Carcinoma: Implications for De‐Escalation and Intensification Strategies
Cancer Medicine · 2026
DOI: 10.1002/cam4.72166 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2026. Verfasst von Hanchuan Xu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, China. Hauptthemen laut MEDLINE: Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Lymph Nodes. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Key Clinical Specialty Construction Program and Key Clinical Specialty Discipline Construction Program of Fujian, China, Youth Talents Project of the Fujian Eagle Program, Fujian Clinical Research Center for Radiation and Therapy of Digestive, Respiratory and Genitourinary Malignancies.
Abstract (Originalsprache)
Background
TNM‐9 Stage IB nasopharyngeal carcinoma (NPC) encompasses markedly heterogeneous risk profiles, yet lacks reliable biomarkers to guide the choice between de‐escalation and intensification strategies. This study aimed to explore the prognostic significance of upper‐ and middle‐neck nodal involvement (UNI and MNI) in this population and how it affects treatment outcomes and prognosis.
Methods
Patients with Stage IB NPC treated between June 2016 and December 2019 at our institution were included. Nodal levels were classified into UNI and MNI. Survival outcomes, including overall survival (OS), progression‐free survival (PFS), distant control (DC), and regional control (RC), were analyzed.
Results
A total of 370 patients were analyzed, with 257 (69.5%) classified in the UNI group and 113 (30.5%) in the MNI group, respectively. MNI was found to be associated with significantly worse prognosis compared to UNI. Specifically, the MNI group had lower 5‐year OS (91.1% vs. 98.8%, p < 0.001), PFS (78.6% vs. 95.6%, p < 0.001), DC (90.2% vs. 98.8%, p < 0.001), and RC (93.3% vs. 98.4%, p = 0.005) than the UNI group. Association analysis revealed that nodal level was significantly associated with other known adverse prognostic factors, including the maximum diameter of positive lymph nodes, matted nodes, and high EBV‐DNA levels (all p < 0.001). Crucially, after multivariate adjustment, nodal level is the only independent prognostic factor.
Conclusion
The nodal level was a critical factor in predicting patient outcomes in Stage IB NPC. These findings are hypothesis‐generating: UNI patients may represent a candidate population for prospective de‐escalation trials, whereas MNI patients may warrant evaluation of intensified or novel strategies in future studies. Prospective validation is required before any change in clinical management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, China.
- Department of Radiology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, China.
- Fujian Key Laboratory of Translational Cancer Medicine, Fuzhou, Fujian, China.
- Department of Radiation Oncology, Xiamen Humanity Hospital, Xiamen, Fujian, China.
- Oncology Department, Zhangzhou Zhengxing Hospital, Zhangzhou, Fujian, China.
ORCID-Profile: Hanchuan Xu, Ziyi Wu, Shaojun Lin, Qiaojuan Guo
Förderung
- National Key Clinical Specialty Construction Program and Key Clinical Specialty Discipline Construction Program of Fujian, China
- Youth Talents Project of the Fujian Eagle Program
- Fujian Clinical Research Center for Radiation and Therapy of Digestive, Respiratory and Genitourinary Malignancies
- Fujian Provincial Natural Science Foundation of China
- Scientific Research Foundation of Fujian Cancer Hospital
- Fujian Cancer Hospital Nasopharyngeal Carcinoma Diagnosis and Treatment Center
- Nasopharyngeal Carcinoma Diagnosis and Treatment Center of Fujian Provincial Medical Peak Excellence Initiative
Zitieren
APA
Xu, H., Chen, X., Huang, D., Yan, Z., Zhu, J., Zhu, L., Zheng, Y., Wu, Z., Pan, C., Zhong, J., Pan, J., Lin, S., Wu, J., & Guo, Q. (2026). Upper Versus Middle‐Neck Involvement in TNM ‐9 Stage IB Nasopharyngeal Carcinoma: Implications for De‐Escalation and Intensification Strategies. Cancer Medicine. https://doi.org/10.1002/cam4.72166
Vancouver
Xu H, Chen X, Huang D, Yan Z, Zhu J, Zhu L, et al. Upper Versus Middle‐Neck Involvement in TNM ‐9 Stage IB Nasopharyngeal Carcinoma: Implications for De‐Escalation and Intensification Strategies. Cancer Medicine. 2026. doi:10.1002/cam4.72166
BibTeX
@article{Xu2026,
author = {Xu, Hanchuan and Chen, Xinlan and Huang, Daqiang and Yan, Zhiwei and Zhu, Jingyu and Zhu, Lili and Zheng, Yahan and Wu, Ziyi and Pan, Caizhu and Zhong, Jing and Pan, Jianji and Lin, Shaojun and Wu, Junxin and Guo, Qiaojuan},
title = {Upper Versus Middle‐Neck Involvement in TNM ‐9 Stage IB Nasopharyngeal Carcinoma: Implications for De‐Escalation and Intensification Strategies},
journal = {Cancer Medicine},
year = {2026},
doi = {10.1002/cam4.72166}
}
EUVIMED